Receptor-mediated activation of ceramidase activity initiates the pleiotropic actions of adiponectin

Nature Medicine

Volumn 17, Issue 1, 2011, Pages 55-63

  Holland, William L ^a   Miller, Russell A ^b   Wang, Zhao V ^a   Sun, Kai ^a   Barth, Brian M ^c   Bui, Hai H ^d   Davis, Kathryn E ^a   Bikman, Benjamin T ^e   Halberg, Nils ^a,f   Rutkowski, Joseph M ^a   Wade, Mark R ^d   Tenorio, Vincent M ^a   Kuo, Ming Shang ^d   Brozinick, Joseph T ^d   Zhang, Bei B ^g   Birnbaum, Morris J ^b   Summers, Scott A ^c,e,h   Scherer, Philipp E ^a  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c Department of Environmental and Radiological Health Sciences   (United States)

^d ELI LILLY AND COMPANY   (United States)

^e DUKE NUS MEDICAL SCHOOL   (Singapore)

^f UNIVERSITY OF COPENHAGEN   (Denmark)

^g MERCK RESEARCH LABORATORIES   (United States)

^h DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENYLATE KINASE; ADIPONECTIN; ADIPONECTIN RECEPTOR 1; ADIPONECTIN RECEPTOR 2; CASPASE 8; CERAMIDASE; CERAMIDE; SPHINGOSINE 1 PHOSPHATE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CATABOLISM; CONTROLLED STUDY; ENZYME ACTIVITY; HEART MUSCLE CELL; INSULIN RESISTANCE; INSULIN SENSITIVITY; LIPID METABOLISM; MALE; MOUSE; NONHUMAN; PANCREAS ISLET BETA CELL; PLEIOTROPY; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; RAT;

ADENYLATE KINASE; ADIPONECTIN; ANIMALS; APOPTOSIS; CALCIUM-CALMODULIN-DEPENDENT PROTEIN KINASE KINASE; CERAMIDASES; CERAMIDES; ENZYME ACTIVATION; GENE EXPRESSION REGULATION; HUMANS; INSULIN; KINETICS; LEPTIN; MICE; MICE, OBESE; MYOCARDIAL INFARCTION; MYOCYTES, CARDIAC; RECEPTORS, ADIPONECTIN;

EID: 78651260799     PISSN: 10788956     EISSN: 1546170X     Source Type: Journal    
DOI: 10.1038/nm.2277     Document Type: Article

References (60)

1. Yamauchi, T. et al. Cloning of adiponectin receptors that mediate antidiabetic metabolic effects. Nature 423, 762-769 (2003).
2. Combs, T.P. et al. A transgenic mouse with a deletion in the collagenous domain of adiponectin displays elevated circulating adiponectin and improved insulin sensitivity. Endocrinology 145, 367-383 (2004).
3. Kim, J.Y. et al. Obesity-associated improvements in metabolic profile through expansion of adipose tissue. J. Clin. Invest. 117, 2621-2637 (2007).
4. Nawrocki, A.R. et al. Mice lacking adiponectin show decreased hepatic insulin sensitivity and reduced responsiveness to peroxisome proliferator-activated receptor gamma agonists. J. Biol. Chem. 281, 2654-2660 (2006).
5. Kubota, N. et al. Disruption of adiponectin causes insulin resistance and neointimal formation. J. Biol. Chem. 277, 25863-25866 (2002).
6. Yamauchi, T. et al. Adiponectin stimulates glucose utilization and fatty-acid oxidation by activating AMP-activated protein kinase. Nat. Med. 8, 1288-1295 (2002).
7. Yamauchi, T. et al. Targeted disruption of AdipoR1 and AdipoR2 causes abrogation of adiponectin binding and metabolic actions. Nat. Med. 13, 332-339 (2007).
8. Iwabu, M. et al. Adiponectin and AdipoR1 regulate PGC-1and mitochondria by Ca2+ and AMPK/SIRT1. Nature 464, 1313-1319 (2010).
9. Schraw, T., Wang, Z.V., Halberg, N., Hawkins, M. & Scherer, P.E. Plasma adiponectin complexes have distinct biochemical characteristics. Endocrinology 149, 2270-2282 (2008).
10. Halberg, N. et al. Systemic fate of the adipocyte-derived factor adiponectin. Diabetes 58, 1961-1970 (2009).
11. Merrill, A.H. Jr. De novo sphingolipid biosynthesis: a necessary, but dangerous, pathway. J. Biol. Chem. 277, 25843-25846 (2002).
12. Holland, W.L. & Summers, S.A. Sphingolipids, insulin resistance, and metabolic disease: new insights from in vivo manipulation of sphingolipid metabolism. Endocr. Rev. 29, 381-402 (2008).
13. Savage, D.B., Petersen, K.F. & Shulman, G.I. Disordered lipid metabolism and the pathogenesis of insulin resistance. Physiol. Rev. 87, 507-520 (2007).
14. Kim, J.K. et al. PKC-theta knockout mice are protected from fat-induced insulin resistance. J. Clin. Invest. 114, 823-827 (2004).
15. Yu, C. et al. Mechanism by which fatty acids inhibit insulin activation of IRS-1 associated phosphatidylinositol 3-kinase activity in muscle. J. Biol. Chem. 277, 50230-50236 (2002).
16. Benoit, S.C. et al. Palmitic acid mediates hypothalamic insulin resistance by altering PKC-theta subcellular localization in rodents. J. Clin. Invest. 119, 2577-2589 (2009).
17. Stratford, S., Hoehn, K.L., Liu, F. & Summers, S.A. Regulation of insulin action by ceramide: dual mechanisms linking ceramide accumulation to the inhibition of Akt/protein kinase B. J. Biol. Chem. 279, 36608-36615 (2004).
18. Mukhopadhyay, A. et al. Direct interaction between the inhibitor 2 and ceramide via sphingolipid-protein binding is involved in the regulation of protein phosphatase 2A activity and signaling. FASEB J. 23, 751-763 (2009).
19. Bourbon, N.A., Yun, J., Berkey, D., Wang, Y. & Kester, M. Inhibitory actions of ceramide upon PKC-epsilon/ERK interactions. Am. J. Physiol. Cell Physiol. 280, C1403-C1411 (2001).
20. Powell, D.J., Hajduch, E., Kular, G. & Hundal, H.S. Ceramide disables 3-phosphoinositide binding to the pleckstrin homology domain of protein kinase B (PKB)/Akt by a PKCzeta-dependent mechanism. Mol. Cell. Biol. 23, 7794-7808 (2003).
21. Fox, T.E. et al. Ceramide recruits and activates protein kinase C zeta (PKC zeta) within structured membrane microdomains. J. Biol. Chem. 282, 12450-12457 (2007).
22. Takabe, K., Paugh, S.W., Milstien, S. & Spiegel, S. "Inside-out" signaling of sphingosine-1-phosphate: therapeutic targets. Pharmacol. Rev. 60, 181-195 (2008).
23. Combs, T.P., Berg, A.H., Obici, S., Scherer, P.E. & Rossetti, L. Endogenous glucose production is inhibited by the adipose-derived protein Acrp30. J. Clin. Invest. 108, 1875-1881 (2001).
24. Berg, A.H., Combs, T.P., Du, X., Brownlee, M. & Scherer, P.E. The adipocyte-secreted protein Acrp30 enhances hepatic insulin action. Nat. Med. 7, 947-953 (2001).
25. Pajvani, U.B. et al. Fat apoptosis through targeted activation of caspase 8: a new mouse model of inducible and reversible lipoatrophy. Nat. Med. 11, 797-803 (2005).
26. Wang, Z.V. et al. PANIC-ATTAC: a mouse model for inducible and reversible beta-cell ablation. Diabetes 57, 2137-2148 (2008).
27. Wencker, D. et al. A mechanistic role for cardiac myocyte apoptosis in heart failure. J. Clin. Invest. 111, 1497-1504 (2003).
28. Brakch, N. et al. Evidence for a role of sphingosine-1 phosphate in cardiovascular remodelling in Fabry disease. Eur. Heart J. 31, 67-76 (2010).
29. Gleason, C.E., Lu, D., Witters, L.A., Newgard, C.B. & Birnbaum, M.J. The role of AMPK and mTOR in nutrient sensing in pancreatic beta-cells. J. Biol. Chem. 282, 10341-10351 (2007).
30. Mao, C. & Obeid, L.M. Ceramidases: regulators of cellular responses mediated by ceramide, sphingosine, and sphingosine-1-phosphate. Biochim. Biophys. Acta 1781, 424-434 (2008).
31. Villa, N.Y. et al. Sphingolipids function as downstream effectors of a fungal PAQR. Mol. Pharmacol. 75, 866-875 (2009).
32. Shaw, R.J. et al. The tumor suppressor LKB1 kinase directly activates AMP-activated kinase and regulates apoptosis in response to energy stress. Proc. Natl. Acad. Sci. USA 101, 3329-3335 (2004).
33. Holland, W.L. & Scherer, P.E. PAQRs: a counteracting force to ceramides? Mol. Pharmacol. 75, 740-743 (2009).
34. Aerts, J.M. et al. Pharmacological inhibition of glucosylceramide synthase enhances insulin sensitivity. Diabetes 56, 1341-1349 (2007).
35. Holland, W.L. et al. Inhibition of ceramide synthesis ameliorates glucocorticoid-, saturated-fat-, and obesity-induced insulin resistance. Cell Metab. 5, 167-179 (2007).
36. Yamashita, T. et al. Enhanced insulin sensitivity in mice lacking ganglioside GM3. Proc. Natl. Acad. Sci. USA 100, 3445-3449 (2003).
37. Zhao, H. et al. Inhibiting glycosphingolipid synthesis improves glycemic control and insulin sensitivity in animal models of type 2 diabetes. Diabetes 56, 1210-1218 (2007).
38. El Bawab, S. et al. Substrate specificity of rat brain ceramidase. J. Lipid Res. 43, 141-148 (2002).
39. Asterholm, I.W. & Scherer, P.E. Enhanced metabolic flexibility associated with elevated adiponectin levels. Am. J. Pathol. 176, 1364-1376 (2010).
40. Puigserver, P. Tissue-specific regulation of metabolic pathways through the transcriptional coactivator PGC1-alpha. Int. J. Obes. (Lond.) 29 (suppl. 1), S5-S9 (2005).
41. Levine, Y.C., Li, G.K. & Michel, T. Agonist-modulated regulation of AMP-activated protein kinase (AMPK) in endothelial cells. Evidence for an AMPK Rac1 Akt endothelial nitric-oxide synthase pathway. J. Biol. Chem. 282, 20351-20364 (2007).
42. Olivera, A. et al. The sphingosine kinase-sphingosine-1-phosphate axis is a determinant of mast cell function and anaphylaxis. Immunity 26, 287-297 (2007).
43. Spiegel, S. & Milstien, S. Sphingosine-1-phosphate: an enigmatic signalling lipid. Nat. Rev. Mol. Cell Biol. 4, 397-407 (2003).
44. Hardie, D.G. AMPK: a key regulator of energy balance in the single cell and the whole organism. Int. J. Obes. (Lond.) 32 (suppl. 4), S7-S12 (2008).
45. Karliner, J.S. Sphingosine kinase and sphingosine 1-phosphate in cardioprotection. J. Cardiovasc. Pharmacol. 53, 189-197 (2009).
46. Van Veldhoven, P.P., Gijsbers, S., Mannaerts, G.P., Vermeesch, J.R. & Brys, V. Human sphingosine-1-phosphate lyase: cDNA cloning, functional expression studies and mapping to chromosome 10q22(1). Biochim. Biophys. Acta 1487, 128-134 (2000).
47. Kupchak, B.R. et al. Probing the mechanism of FET3 repression by Izh2p overexpression. Biochim. Biophys. Acta 1773, 1124-1132 (2007).
48. King, C.C. et al. Sphingosine is a novel activator of 3-phosphoinositide-dependent kinase 1. J. Biol. Chem. 275, 18108-18113 (2000).
49. Clackson, T. et al. Redesigning an FKBP-ligand interface to generate chemical dimerizers with novel specificity. Proc. Natl. Acad. Sci. USA 95, 10437-10442 (1998).
50. Pajvani, U.B. et al. Structure-function studies of the adipocyte-secreted hormone Acrp30/adiponectin. Implications for metabolic regulation and bioactivity. J. Biol. Chem. 278, 9073-9085 (2003).
51. Li, Z. et al. Liver-specific deficiency of serine palmitoyltransferase subunit 2 decreases plasma sphingomyelin and increases apolipoprotein E levels. J. Biol. Chem. 284, 27010-27019 (2009).
52. Perry, D.K., Bielawska, A. & Hannun, Y.A. Quantitative determination of ceramide using diglyceride kinase. Methods Enzymol. 312, 22-31 (2000).
53. Berglund, E.D. et al. Fibroblast growth factor 21 controls glycemia via regulation of hepatic glucose flux and insulin sensitivity. Endocrinology 150, 4084-4093 (2009).
54. Stein, D.T. et al. The insulinotropic potency of fatty acids is influenced profoundly by their chain length and degree of saturation. J. Clin. Invest. 100, 398-403 (1997).
55. Mao, C. et al. Cloning and characterization of a novel human alkaline ceramidase. A mammalian enzyme that hydrolyzes phytoceramide. J. Biol. Chem. 276, 26577-26588 (2001).
56. Mu, J., Brozinick, J.T. Jr. Valladares, O., Bucan, M. & Birnbaum, M.J. A role for AMP-activated protein kinase in contraction- and hypoxia-regulated glucose transport in skeletal muscle. Mol. Cell 7, 1085-1094 (2001).
57. Burger, D. et al. Erythropoietin protects cardiomyocytes from apoptosis via upregulation of endothelial nitric oxide synthase. Cardiovasc. Res. 72, 51-59 (2006).
58. Hohmeier, H.E. et al. Isolation of INS-1-derived cell lines with robust ATP-sensitive K+ channel-dependent and -independent glucose-stimulated insulin secretion. Diabetes 49, 424-430 (2000).
59. Hohmeier, H.E., Tran, V.V., Chen, G., Gasa, R. & Newgard, C.B. Inflammatory mechanisms in diabetes: lessons from the beta-cell. Int. J. Obes. Relat. Metab. Disord. 27 (suppl. 3), S12-S16 (2003).
60. He, L. & Fox, M.H. Variation of heat shock protein 70 through the cell cycle in HL-60 cells and its relationship to apoptosis. Exp. Cell Res. 232, 64-71 (1997).